Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Williams, Meininger tasked with validating Sana’s platforms in the clinic

The ex-Codiak and Vertex execs bring translational and clinical expertise in new modalities

By Lauren Martz, Executive Director, Biopharma Intelligence
April 10, 2023 11:53 PM UTC

As Sana heads into the clinic, it’s bringing on two new modality veterans to make the transition. The first order of business for Doug Williams and Gary Meininger will be rapid technology de-risking. 

On Monday, Sana Biotechnology Inc. (NASDAQ:SANA) announced that Doug Williams will step into the new president of R&D role, and that Gary Meininger will become the new CMO. Meininger replaces Sunil Agarwal, who will leave the company during the management transition. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Biogen Inc.

Codiak Biosciences Inc.

Roche

Sana Biotechnology Inc.

Vertex Pharmaceuticals Inc.

BCIQ Target Profiles

CD19